VAXY LIMITED

Company Registration Number:
13194462 (England and Wales)

Unaudited micro entity accounts for the year ended 29 February 2024

Period of accounts

Start date: 01 March 2023

End date: 29 February 2024

VAXY LIMITED

Contents of the Financial Statements

for the Period Ended 29 February 2024

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Footnotes to the Balance Sheet - 8

VAXY LIMITED

Company Information

for the Period Ended 29 February 2024




Director: Sisira Pushpa Kumara Weerasinghe
Registered office: 25
Enfield Road
Brentford
England
TW8 9NY
Company Registration Number: 13194462 (England and Wales)

VAXY LIMITED

Directors' Report Period Ended 29 February 2024

The directors present their report with the financial statements of the company for the period ended 29 February 2024

Principal Activities

Retail sale via mail order houses or via Internet

Directors

The directors shown below have held office during the whole of the period from 01 March 2023 to 29 February 2024
Sisira Pushpa Kumara Weerasinghe

This report was approved by the board of directors on 15 April 2024
And Signed On Behalf Of The Board By:

Name: Sisira Pushpa Kumara Weerasinghe
Status: Director

VAXY LIMITED

Profit and Loss Account

for the Period Ended 29 February 2024


2024
£

2023
£
Turnover 108,927 91,267
Income from coronavirus (COVID-19) business support grants 0 0
Other Income 0 0
Cost of Materials ( 17,491 ) ( 44,987 )
Staff Costs ( 13,717 ) ( 12,453 )
Depreciation and Writeoffs ( 0 ) ( 0 )
Other charges ( 76,925 ) ( 32,962 )
Tax on Profit ( 151 ) ( 164 )
Profit or (Loss) for Period 643 701

VAXY LIMITED

Balance sheet

As at 29 February 2024


2024
£

2023
£
Called up share capital not paid: 0 0
Fixed Assets: 0 0
Current assets: 34,282 30,663
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year: ( 33,639 ) ( 29,961 )
Net current assets (liabilities): 643 702
Total assets less current liabilities: 643 702
Creditors: amounts falling due after more than one year: ( 0 ) ( 0 )
Provision for liabilities: ( 0 ) ( 0 )
Accruals and deferred income: ( 0 ) ( 0 )
Total net assets (liabilities): 643 702
Capital and reserves: 643 702

VAXY LIMITED

Balance sheet continued

For the year ending 29 February 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 15 April 2024
And Signed On Behalf Of The Board By:

Name: Sisira Pushpa Kumara Weerasinghe
Status: Director

The notes form part of these financial statements

VAXY LIMITED

Footnotes to the Financial Statements

for the Period Ended 29 February 2024

  • 1. Employee Information

    Average number of employees: 1

VAXY LIMITED

Footnotes to the Financial Statements

for the Period Ended 29 February 2024

  • 2. Off balance sheet disclosure

    No